Celcuity Inc. is a clinical-stage biotechnology company focused on developing targeted therapies for solid tumor indications. Its lead candidate, gedatolisib, is a pan-class I PI3K/AKT/mTOR pathway inhibitor administered intravenously. Celcuity is advancing gedatolisib in Phase 3 trials (VIKTORIA-1, VIKTORIA-2) for HR+/HER2- advanced breast cancer and a Phase 1b/2 trial (CELC-G-201) for metastatic castration-resistant prostate cancer. The FDA accepted Celcuity's NDA for gedatolisib in January 2026 with a PDUFA target date of July 17, 2026.
expected 2026-12-30
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-26 | 2025-12-31 | 0001493152-26-012801 | EDGAR | 72K words |
| 2025-03-31 | 2024-12-31 | 0001641172-25-001826 | EDGAR | 63K words |
| 2024-03-27 | 2023-12-31 | 0001493152-24-011549 | EDGAR | 63K words |
| 2023-03-23 | 2022-12-31 | 0001493152-23-008724 | EDGAR | 71K words |
| 2022-03-23 | 2021-12-31 | 0001493152-22-007560 | EDGAR | 67K words |
| 2021-02-16 | 2020-12-31 | 0001654954-21-001743 | EDGAR | 51K words |
| 2020-03-13 | 2019-12-31 | 0001654954-20-002595 | EDGAR | 46K words |
| 2019-03-01 | 2018-12-31 | 0001144204-19-011631 | EDGAR | 50K words |
| 2018-03-15 | 2017-12-31 | 0001144204-18-014940 | EDGAR | 50K words |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-11-05 | 2026-09-30 | 0001193125-26-450161 | EDGAR | 31K words |
| 2026-08-13 | 2026-06-30 | 0001193125-26-349608 | EDGAR | 27K words |
| 2025-11-13 | 2025-09-30 | 0001493152-25-022401 | EDGAR | 31K words |
| 2025-08-14 | 2025-06-30 | 0001641172-25-024148 | EDGAR | 27K words |
| 2025-05-15 | 2025-03-31 | 0001641172-25-011053 | EDGAR | 19K words |
| 2024-11-14 | 2024-09-30 | 0001493152-24-046022 | EDGAR | 21K words |
| 2024-08-14 | 2024-06-30 | 0001493152-24-032372 | EDGAR | 21K words |
| 2024-05-15 | 2024-03-31 | 0001493152-24-019974 | EDGAR | 16K words |
| 2023-11-13 | 2023-09-30 | 0001493152-23-040434 | EDGAR | 18K words |
| 2023-08-11 | 2023-06-30 | 0001493152-23-027869 | EDGAR | 17K words |
| 2023-05-15 | 2023-03-31 | 0001493152-23-017491 | EDGAR | 15K words |
| 2022-11-10 | 2022-09-30 | 0001493152-22-031433 | EDGAR | 40K words |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-11-05 | 0001193125-26-449757 | EDGAR | 5K words |
| 2026-10-02 | 0001193125-26-411297 | EDGAR | 1K words |
| 2026-09-30 | 0001193125-26-408353 | EDGAR | 2K words |
| 2026-08-26 | 0001193125-26-365975 | EDGAR | 2K words |
| 2026-08-13 | 0001193125-26-349227 | EDGAR | 5K words |
| 2026-07-15 | 0001493152-26-033223 | EDGAR | 3K words |
| 2026-03-25 | 0001493152-26-012668 | EDGAR | 4K words |
| 2026-02-12 | 0001493152-26-006444 | EDGAR | 1K words |
| 2025-11-17 | 0001493152-25-023897 | EDGAR | 1K words |
| 2025-11-12 | 0001493152-25-021903 | EDGAR | 4K words |
162 total filings indexed. 131 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001603454 |
| Ticker | CELC |
| Exchange | Nasdaq |
| SIC | 8071: Services-Medical Laboratories |
| Incorporated | DE |
| Website | https://www.celcuity.com |
| Listed | 2017-09-20 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/CELC (~200 tokens, structured JSON with cryptographic provenance)